Adicet Bio Inc (NAS:ACET)
$ 1.345 -0.095 (-6.6%) Market Cap: 110.52 Mil Enterprise Value: -20.87 Mil PE Ratio: 0 PB Ratio: 0.34 GF Score: 57/100

resTORbio, Inc. at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 10:55PM GMT
Unidentified Analyst

(technical difficulty) Merrill Lynch. It is my pleasure to introduce our next presenting company, resTORbio. Presenting for resTOR this afternoon is the CEO, Chen Schor. And Chen is going through a list of slides, and then if you have questions at the end, we'll take some during Q&A.

And with that, I'll turn it over to Chen.

Chen Schor
resTORbio, Inc. - Co-Founder, President, CEO & Director

Good afternoon, and thank you for your interest in resTORbio. I'm Chen Schor, and I'm President and CEO for resTORbio. And I'm very glad to be here with you today and update you about our progress at resTORbio.

I want to start with a question. I want to start with a question. How -- why does this happen? How come most chronic diseases present themselves when we are 60s or 70s? How come when we're older, there's a decline in our immune function and we see more severe respiratory tract infections? So what we see is actually the biggest risk factor for most chronic diseases is aging. And we used to think about aging as just random wear

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot